DE102004014983A1 - Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung - Google Patents

Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung Download PDF

Info

Publication number
DE102004014983A1
DE102004014983A1 DE102004014983A DE102004014983A DE102004014983A1 DE 102004014983 A1 DE102004014983 A1 DE 102004014983A1 DE 102004014983 A DE102004014983 A DE 102004014983A DE 102004014983 A DE102004014983 A DE 102004014983A DE 102004014983 A1 DE102004014983 A1 DE 102004014983A1
Authority
DE
Germany
Prior art keywords
polypeptides
tnf ligand
ligand family
relates
members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004014983A
Other languages
English (en)
Inventor
Klaus Pfizenmaier
Peter Scheurich
Ingo Grunwald
Anja Krippner-Heidenreich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Stuttgart
Original Assignee
Universitaet Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Stuttgart filed Critical Universitaet Stuttgart
Priority to DE102004014983A priority Critical patent/DE102004014983A1/de
Priority to JP2007504361A priority patent/JP2007530021A/ja
Priority to PCT/EP2005/003158 priority patent/WO2005103077A1/de
Priority to US10/594,189 priority patent/US8927205B2/en
Priority to PL05716360T priority patent/PL1727833T3/pl
Priority to CA2563754A priority patent/CA2563754C/en
Priority to EP05716360.2A priority patent/EP1727833B1/de
Priority to PT57163602T priority patent/PT1727833E/pt
Priority to DK05716360.2T priority patent/DK1727833T3/da
Priority to ES05716360.2T priority patent/ES2439896T3/es
Priority to AU2005235669A priority patent/AU2005235669B2/en
Publication of DE102004014983A1 publication Critical patent/DE102004014983A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/811—Peptides or proteins is immobilized on, or in, an inorganic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

Die vorliegende Erfindung betrifft Polypeptide, welche mindestens drei Monomere eines Mitglieds der TNF-Ligandenfamilie als Komponenten A und mindestens zwei Peptid-Linker als Komponenten B umfassen, wobei die Peptid-Linker die Monomere des Mitglieds der TNF-Ligandenfamilie miteinander verknüpfen. Des weiteren betrifft die vorliegende Erfindung die Verwendung dieser Polypeptide zur Behandlung von Erkrankungen, zur Herstellung eines Arzneimittels oder einer Vakzine. Darüber hinaus betrifft die Erfindung Verfahren zur Herstellung und Isolierung dieser Polypeptide sowie für die Polypeptide codierende Nukleinsäuren, diese enthaltende Vektoren, mit diesem transfizierte Wirtszellen und pharmazeutische Zusammensetzungen, welche diese genannten Erfindungsgegenstände enthalten.
DE102004014983A 2004-03-26 2004-03-26 Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung Withdrawn DE102004014983A1 (de)

Priority Applications (11)

Application Number Priority Date Filing Date Title
DE102004014983A DE102004014983A1 (de) 2004-03-26 2004-03-26 Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
JP2007504361A JP2007530021A (ja) 2004-03-26 2005-03-24 Ｔｎｆリガンドファミリーメンバーの組換えポリペプチドおよびその使用
PCT/EP2005/003158 WO2005103077A1 (de) 2004-03-26 2005-03-24 Rekombinante polypeptide der mitglieder der tnf ligandenfamilie und deren verwendung
US10/594,189 US8927205B2 (en) 2004-03-26 2005-03-24 Recombinant polypeptides of the members of the TNF ligand family and use thereof
PL05716360T PL1727833T3 (pl) 2004-03-26 2005-03-24 Rekombinowane polipeptydy członków rodziny ligandów TNF i ich zastosowanie
CA2563754A CA2563754C (en) 2004-03-26 2005-03-24 Recombinant polypeptides of the members of the tnf ligand family and use thereof
EP05716360.2A EP1727833B1 (de) 2004-03-26 2005-03-24 Rekombinante polypeptide der mitglieder der tnf ligandenfamilie und deren verwendung
PT57163602T PT1727833E (pt) 2004-03-26 2005-03-24 Polipeptídeos recombinantes dos membros da família de ligandos do tnf e respetiva utilização
DK05716360.2T DK1727833T3 (da) 2004-03-26 2005-03-24 Rekombinante polypeptider af medlemmer af TNF-ligandfamilien og anvendelse deraf
ES05716360.2T ES2439896T3 (es) 2004-03-26 2005-03-24 Polipéptidos recombinantes de los miembros de la familia de ligandos de TNF y su utilización
AU2005235669A AU2005235669B2 (en) 2004-03-26 2005-03-24 Recombinant polypeptides of the members of the TNF ligand family and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004014983A DE102004014983A1 (de) 2004-03-26 2004-03-26 Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung

Publications (1)

Publication Number Publication Date
DE102004014983A1 true DE102004014983A1 (de) 2005-10-20

Family

ID=34962642

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004014983A Withdrawn DE102004014983A1 (de) 2004-03-26 2004-03-26 Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung

Country Status (11)

Country Link
US (1) US8927205B2 (de)
EP (1) EP1727833B1 (de)
JP (1) JP2007530021A (de)
AU (1) AU2005235669B2 (de)
CA (1) CA2563754C (de)
DE (1) DE102004014983A1 (de)
DK (1) DK1727833T3 (de)
ES (1) ES2439896T3 (de)
PL (1) PL1727833T3 (de)
PT (1) PT1727833E (de)
WO (1) WO2005103077A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
WO2018185247A1 (en) * 2017-04-06 2018-10-11 Universität Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
US12173046B2 (en) 2019-06-24 2024-12-24 Universitat Stuttgart TNFR2 agonists with improved stability

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1774017B1 (de) 2004-07-26 2013-05-15 Pfenex Inc. Verfahren zur verbesserten proteinexpression durch strain-engineering
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP3103875A1 (de) 2008-07-21 2016-12-14 Apogenix AG Einkettige tnfsf-moleküle
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
US8461311B2 (en) 2010-06-08 2013-06-11 Washington University TRAIL trimers, methods and uses therefor
US9127081B2 (en) * 2012-05-10 2015-09-08 Washington University Tumor targeted TNF-related apoptosis inducing ligand fusion polypeptide and nucleic acids encoding the same
WO2013186329A1 (en) * 2012-06-13 2013-12-19 Scil Proteins Gmbh Human fusion proteins comprising single chain tnfalpha and targeting domains
US10048271B2 (en) 2012-12-11 2018-08-14 Albert Einstein College Of Medicine, Inc. Methods for high throughput receptor:ligand identification
NO2776305T3 (de) 2014-04-23 2018-01-27
PT3480213T (pt) * 2014-06-18 2020-02-04 Albert Einstein College Medicine Polipéptidos syntac e utilizações dos mesmos
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
EP3253785B1 (de) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Neuartige egfr-bindende proteine
BR112017023646A2 (pt) 2015-05-04 2018-07-17 Apogenix Ag proteínas agonistas de receptor de cd40 de cadeia simples
CN107922483B (zh) 2015-07-16 2021-07-30 纳维格蛋白质有限公司 新型免疫球蛋白结合蛋白及其在亲和纯化中的用途
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
EP3364995B1 (de) 2015-10-23 2021-08-04 Apogenix AG Einkettige cd27-rezeptor-agonisten-proteine
EP3365363A1 (de) 2015-10-23 2018-08-29 Apogenix AG Einkettige gitr-rezeptor-agonisten-proteine
JP6873119B2 (ja) 2015-10-23 2021-05-19 アポジェニックス アーゲー 一本鎖ｌｉｇｈｔ受容体アゴニストタンパク質
WO2017072080A1 (en) 2015-10-28 2017-05-04 Apogenix Ag Single-chain tl1a receptor agonist proteins
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
AU2017260274A1 (en) 2016-05-04 2018-11-01 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
AU2017266905B2 (en) 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US11505591B2 (en) 2016-05-18 2022-11-22 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EA037848B1 (ru) * 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
CA3030208A1 (en) 2016-08-11 2018-02-15 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin binding proteins
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
KR102903340B1 (ko) 2017-01-06 2025-12-26 이오반스 바이오테라퓨틱스, 인크. 종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
JP7664020B2 (ja) 2017-01-06 2025-04-17 アイオバンス バイオセラピューティクス，インコーポレイテッド カリウムチャネルアゴニストによる腫瘍浸潤リンパ球の増殖及びその治療的使用
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
MA50871A (fr) 2017-05-10 2020-03-18 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
WO2019103857A1 (en) 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
JP7565795B2 (ja) 2017-12-15 2024-10-11 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
CN111886241A (zh) 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
CA3123986A1 (en) 2018-12-18 2020-06-25 Navigo Proteins Gmbh Novel folr1 specific binding proteins for cancer diagnosis and treatment
KR20210136050A (ko) 2019-03-01 2021-11-16 이오반스 바이오테라퓨틱스, 인크. 액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
EP4041410A4 (de) 2019-10-08 2023-12-06 Fred Hutchinson Cancer Center Gentechnisch hergestellte trimere cd70-proteine und deren verwendungen
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A4 (de) 2020-09-09 2024-10-09 Cue Biopharma, Inc. Mhc klasse ii t-zell-modulierende multimere polypeptide zur behandlung von typ 1 diabetes mellitus (t1d) und verfahren zur verwendung davon
JP2023544347A (ja) 2020-10-01 2023-10-23 イミューニコム， インコーポレイテッド リガンドの浸出の低減
WO2024098024A1 (en) 2022-11-04 2024-05-10 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
CA2390095C (en) 1999-11-10 2013-01-08 M. Rigdon Lentz Method and system to remove cytokine inhibitor in patients
US6379708B1 (en) 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
GB0015426D0 (en) 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
DE10113776B4 (de) * 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
DE10144252A1 (de) * 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
US20030185845A1 (en) * 2001-11-16 2003-10-02 Steen Klysner Novel immunogenic mimetics of multimer proteins
CA2467052A1 (en) 2001-11-16 2003-05-22 Pharmexa A/S Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
FR2840307B1 (fr) * 2002-05-30 2006-07-07 Centre Nat Rech Scient Nouvelles molecules multimeriques, leur procede de preparation, et leur utilisation pour la preparation de medicaments
DE10247755B4 (de) 2002-10-14 2006-01-19 Pfizenmaier, Klaus, Prof. Dr. Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
AU2004235875A1 (en) * 2003-05-09 2004-11-18 Pharmexa A/S Immunogenic human TNF alpha analogues with reduced cytotoxicity and methods of their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012130471A1 (en) * 2011-04-01 2012-10-04 Universität Stuttgart Recombinant tnf ligand family member polypeptides with antibody binding domain and uses thereof
US9822179B2 (en) 2011-04-01 2017-11-21 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor
US10570206B2 (en) 2011-04-01 2020-02-25 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses thereof
EP3670536A3 (de) * 2011-04-01 2020-10-07 Universität Stuttgart Rekombinante polypeptidmitglieder der tnf-liganden-familien mit antikörperbindender domäne und verwendungen dafür
WO2018185247A1 (en) * 2017-04-06 2018-10-11 Universität Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
US11142558B2 (en) 2017-04-06 2021-10-12 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
US12065472B2 (en) 2017-04-06 2024-08-20 Universität Stuttgart Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity
US12173046B2 (en) 2019-06-24 2024-12-24 Universitat Stuttgart TNFR2 agonists with improved stability

Also Published As

Publication number Publication date
CA2563754C (en) 2016-06-28
WO2005103077A1 (de) 2005-11-03
AU2005235669B2 (en) 2012-04-19
PT1727833E (pt) 2013-12-23
EP1727833B1 (de) 2013-09-18
PL1727833T3 (pl) 2014-03-31
JP2007530021A (ja) 2007-11-01
US8927205B2 (en) 2015-01-06
AU2005235669A1 (en) 2005-11-03
US20070286843A1 (en) 2007-12-13
EP1727833A1 (de) 2006-12-06
DK1727833T3 (da) 2014-01-13
CA2563754A1 (en) 2005-11-03
ES2439896T3 (es) 2014-01-27

Similar Documents

Publication Publication Date Title
EP1317488B1 (de) ORTSSPEZIFISCHE, ANTIKÖRPERVERMITTELTE AKTIVIERUNG PROAPOPTOTISCHER ZYTOKINE: AMAIZe (ANTIBODY-MEDIATED APOPTOSIS INDUCING ZYTOKINE)
DE69736712T2 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69227693T2 (de) Hybride cytokine
Marchbank et al. Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects
DE69736634T2 (de) Antagonisten des intestinotrophen glp-2 peptides
Johnson et al. Coacervate delivery of HB‐EGF accelerates healing of type 2 diabetic wounds
DE69635675T2 (de) Verkürzter aus einer gliazelllinie gewonnener neurotropher faktor
WO2008090958A1 (ja) ドメイン交換された遺伝子組換え抗体組成物
CN107188950A (zh) Fgf21突变体及其用途
DE1003781T1 (de) Interleukin-18 bindende proteine, deren herstellung und verwendung
DE19757250A1 (de) Insulin-like growth factor binding protein und seine Verwendung
DE602005001445D1 (de) N-terminal monopegylierte menschliche wachstumshormon-konjugate, verfahren zu ihrer herstellung und ihre anwendung
DE69132581T3 (de) Verbesserte chimäre toxine
DE60028565T2 (de) Vaskuläre endothelzellen wachstumsfaktor (vegf) varianten und dessen verwendungen
DE60207043T2 (de) Histidin-reiches glykoprotein (hrgp) zur inhibierung der angiogenese
DE102005036542A1 (de) CTL-Prodrug
DE102015003503A1 (de) Spezifisch Amyloid-Beta bindende Peptide und deren Verwendung für die Therapie und Diagnose der Alzheimerschen Demenz
JPWO2016133197A1 (ja) Ｆｃ融合高親和性ＩｇＥ受容体α鎖
Cai et al. Apratyramide, a marine-derived peptidic stimulator of VEGF-A and other growth factors with potential application in wound healing
DE60103078T2 (de) Chemokin mutanten zur behandlung multipler sklerose
DE112005000737T5 (de) Mit Heparansulfat-Zuckerketten modifizierte Heparin-bindende Proteine, Verfahren zur Erzeugung derselben und Arzneimittel, welche dieselben enthalten
AT506150B1 (de) Zyklisches und cystein-freies peptid
DE68923496T2 (de) Verfahren zur Herstellung von motilinähnlichen Polypeptiden und seine Expression.
EP3271374B1 (de) Spezifisch a-beta-spezies bindende peptide für die therapie und/oder die diagnose der alzheimerschen demenz
WO2011120859A1 (de) Fusionsprotein und dessen verwendungen

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20141001